KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Raw Materials (2016 - 2026)

Supernus Pharmaceuticals has reported Raw Materials over the past 14 years, most recently at $31.8 million for Q4 2025.

  • Quarterly Raw Materials rose 186.09% to $31.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.8 million through Dec 2025, up 186.09% year-over-year, with the annual reading at $31.8 million for FY2025, 186.09% up from the prior year.
  • Raw Materials was $31.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $57.0 million in the prior quarter.
  • Over five years, Raw Materials peaked at $57.0 million in Q3 2025 and troughed at $7.3 million in Q4 2021.
  • The 5-year median for Raw Materials is $16.1 million (2023), against an average of $18.8 million.
  • Year-over-year, Raw Materials crashed 73.5% in 2022 and then surged 392.51% in 2025.
  • A 5-year view of Raw Materials shows it stood at $7.3 million in 2021, then surged by 238.84% to $24.8 million in 2022, then plummeted by 34.43% to $16.3 million in 2023, then crashed by 31.63% to $11.1 million in 2024, then soared by 186.09% to $31.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Raw Materials are $31.8 million (Q4 2025), $57.0 million (Q3 2025), and $8.4 million (Q2 2025).